Name: Cyclosporine
Brand: Selleck Chemicals
SKU: S1514
Availability: InStock
Rating: 5 (14 reviews)

Jump to

Quality Control

Batch: Purity: 99.92%

99.92

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism Drug Metabolite
Other phosphatase Inhibitors	Osunprotafib (ABBV-CLS-484) SHP099 Hydrochloride RMC-4550 SHP099 GSK2830371 Batoprotafib (TNO155) β-Glycerophosphate sodium salt hydrate NSC87877 TPI-1 Sanguinarine chloride

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (83.15 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	2%DMSO 1 40%PEG300 2 2%Tween80 3 56%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.000mg/ml (2.49mM)	Taking the 1 mL working solution as an example, add 20 μL of 150 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 20 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 560 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	1202.61	Formula	C₆₂H₁₁₁N₁₁O₁₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	79217-60-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Mechanism of Action

Targets/IC₅₀/Ki	calcineurin phosphatase
In vitro	Cyclosporine induces phenotypic changes, including invasiveness of non-transformed cells, by a cell-autonomous mechanism. This compound's treatment of adenocarcinoma cells results in striking morphological alterations, including membrane ruffling and numerous pseudopodial protrusions, increased cell motility, and anchorage-independent (invasive) growth. It has potent immunosuppressive properties, reflecting its ability to block the transcription of cytokine genes in activated T cells. This chemical, through formation of a complex with cyclophilin, inhibits the phosphatase activity of calcineurin, which regulates nuclear translocation and subsequent activation of NFAT transcription factors. It also blocks the activation of JNK and p38 signaling pathways triggered by antigen recognition, making CsA a highly specific inhibitor of T cell activation. Its-mediated inhibition of the biliary excretion of MPAG by the Mrp2 transporter is the mechanism responsible for the interaction between this compound and mycophenolate mofetil (MMF). It inhibits biochemical and morphological differentiation of skeletal muscle cells while having a minimal effect on proliferation.
In vivo	Cyclosporine enhances tumour growth in immunodeficient SCID-beige mice. This compound inhibits muscle regeneration after induced trauma in mice. It peaks at 1 hour in blood, spleen, and kidney, with higher concentrations in spleen and kidney than in blood.
References	[1] https://pubmed.ncbi.nlm.nih.gov/10028970/ [2] https://pubmed.ncbi.nlm.nih.gov/10878286/ [3] https://pubmed.ncbi.nlm.nih.gov/15816878/ [4] https://pubmed.ncbi.nlm.nih.gov/9763451/ [5] https://pubmed.ncbi.nlm.nih.gov/10573076/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05702931	Not yet recruiting	Hyperglycemia\|Renal Transplant Complication Primary Non-Function\|Diabetes	Rigshospitalet Denmark\|Aarhus University Hospital\|Odense University Hospital	April 1 2024	Phase 4
NCT05955924	Recruiting	Non-melanoma Skin Cancer\|Carcinoma Squamous Cell\|Carcinoma Basal Cell\|Keratinocyte Carcinoma	Women''s College Hospital\|Canadian Institutes of Health Research (CIHR)\|University Health Network Toronto\|NOW Foods	August 28 2023	Phase 3
NCT04989686	Recruiting	Immunosuppression	Children''s Hospital of Philadelphia\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	June 8 2023	--
NCT05745701	Completed	Healthy	Pfizer	February 22 2023	Phase 1
NCT05056779	Withdrawn	Moderate-to-severe Atopic Dermatitis	Galderma R&D	January 2023	Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the difference between S2286 (it) and S1514 (this compound)?

Answer:
It is a mixture of Cyclosporine A, derivatives of Cyclosporine A, and salts of Cyclosporine A. Cyclosporine A is an especially useful component of this compound.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Cyclosporine phosphatase inhibitor

Chemical Structure

Molecular Weight: 1202.61